Joseph Mikhael, MD, Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, discusses types of immunotherapy for patients with multiple myeloma. Dr Mikhael explains BCMA, antibody-drug conjugates, CAR T-cell therapy, and bispecific therapies. The first anti-BCMA CAR T-cell therapy for adults with relapsed/refractory multiple myeloma was approved by the FDA in March 2021.